<DOC>
	<DOCNO>NCT01302236</DOCNO>
	<brief_summary>The purpose study determine whether eplerenone effective treatment blood pressure , heart function , renal function elderly hypertensive stage1 ( eGFR &gt; =90ml/min/1.73m2 ) stage2 ( eGFR 60-89ml/min/1.73m2 ) chronic kidney disease ( CKD ) patient .</brief_summary>
	<brief_title>Effect Eplerenone Elderly Hypertensive Early Stage Chronic Kidney Disease ( CKD ) Patients</brief_title>
	<detailed_description>Chronic kidney disease ( CKD ) report affect 11 % population . This number much high elderly population may high 30 % . CKD independent risk factor cardiovascular disease ( CVD ) . This call `` Cardio-renal Continuum '' . The renin-angiotensin-aldosterone system ( RAS ) play pivotal role cardiovascular renal function . The increased oxidative stress activate RAS vascular endothelium one important factor development Cardio-renal Continuum . The blockade RAS angiotensin I convert enzyme inhibitor ( ACEIs ) and/or angiotensin receptor blocker ( ARBs ) report ameliorate renal disease CVD ; however , completely suppress RAS may induce aldosterone breakthrough play important role development CVD . Eplerenone , selective aldosterone blocker , effective essential hypertension ; however , little known effect eplerenone heart kidney function elderly hypertensive CKD patient . In study , assess efficacy eplerenone heart kidney function elderly hypertensive early stage ( stage1 ( eGFR &gt; =90ml/min/1.73m2 ) stage2 ( eGFR 60-89ml/min/1.73m2 ) ) CKD patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Clinical diagnosis stage1 ( eGFR &gt; =90ml/min/1.73m2 ) stage2 ( eGFR 60 89ml/min/1.73m2 ) chronic kidney disease Clinical diagnosis Hypertension ( Blood pressure &gt; =140/90mmHg ) Elderly people ( &gt; =65 year old ) The patient already take eplerenone Stage3 ( eGFR 3060 ml/min/1.73m2 ) , stage4 ( eGFR 1530 ml/min/1.73m2 ) stage5 ( eGFR &lt; 15 ml/min/1.73m2 ) CKD patient The patient receive hemodialysis peritoneal dialysis The patient take itraconazole , ritonavir nelfinavir The patient take potassiumsparing diuretic potassium supplement The patient hyperkalemia ( &gt; =5.5mEq/ml ) Severe heart failure ( &gt; =NYHA class III ) Insulin dependent diabetic mellitus poor control insulin independent diabetic mellitus ( &gt; =HbA1c 9.0 &amp; ) Severe liver dysfunction ( five fold increase AST ALT standard value )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Early stage chronic kidney disease</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Eplerenone</keyword>
</DOC>